News | | More »

Annual Report 2021 Active Biotech AB (publ)

Press Release

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Press Release

Active Biotech Interim Report Q1 2022

Press Release

Active Biotech: Notice of annual general meeting of shareholders

Press Release

Aktiespararna: Analysis Active Biotech: “Breddad klinisk portfölj” (in Swedish)

Equity research and Presentations

Redeye: Advancing Three Active Projects

Equity research and Presentations

Active Biotech: Year End Report 2021

Press Release

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Press Release

Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma

Press Release

Active Biotechs presentation at Aktiespararnas “Aktiedagen Lund” January 31, 2022

Equity research and Presentations

We Develop New Treatments for Cancer and Inflammatory Diseases

We leverage our extensive knowledge and previously generated documentation on our assets to develop novel treatments for specialist indications with high medical need and commercial value within cancer and inflammatory eye disorders. We have a stringent focus on our projects in multiple myeloma, uveitis and in solid tumors for naptumomab in partnership with NeoTX.

Novel treatments for specialist indications

Pipeline

Disease Area
Discovery
Preclinical
Phase I
Phase II
Phase III
Partner
Hematological malignancies
Tasquinimod Multiple myeloma*
Tasquinimod Myelofibrosis
Inflammatory eye disorders
Laquinimod Uveitis
Solid tumors
Naptumomab Combination with docetaxel in non-small cell lung cancer
Naptumomab Combination with anti-PDL1 (durvalumab) in solid tumors
Study ongoing
* In an academic partnership with the Abramson Cancer Center, Philadelphia, University of Pennsylvania

Our project portfolio comprises small, orally active immunomodulatory molecules as well as antibody-based immunotherapy. We have three projects in our project portfolio, Tasquinimod, Laquinimod and Naptumomab. Read more about Active Biotechs projects »

Uveitis can Lead to Severe Eye Problems Including Blindness

Laquinimod

Multiple Myeloma a Blood Cancer with Unmet Medical Need

Tasquinimod